false
OasisLMS
Login
Catalog
Kidney Week 2026 Early Program On-Demand - Advance ...
Kidney-Targeted AAVs
Kidney-Targeted AAVs
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Dr. Harman Dasulkan described developing AAV vectors for kidney gene therapy through accelerated evolution rather than rational design. His team diversified viral surface regions and selected variants across mouse, pig, nonhuman-primate, and human kidney-organoid models, aiming to identify capsids that work across species. Kidney-directed selection produced variants such as K20, which showed strong expression—especially in proximal tubules—while retaining similar kidney and liver viral DNA levels to natural AAVs, suggesting improved post-entry transduction. Retrograde ureteral delivery in animal models further enabled broad kidney expression with substantially lower liver exposure than systemic dosing; optimizing delivery conditions also improved access to additional kidney cell types. The platform may support gene replacement, including PKD2, and expression of non-coding RNAs. Key challenges remain: identifying the capsid’s mechanism and receptor, confirming performance in diseased kidneys and humans, assessing antibody effects and redosing, and defining which specific cell types are transduced.
Asset Caption
Aravind Asokan, PhD
Meta Tag
Speaker
Aravind Asokan
Keywords
AAV vectors
kidney gene therapy
accelerated evolution
proximal tubules
retrograde ureteral delivery
PKD2
Aravind Asokan
×
Please select your language
1
English